ArticlePharmacoEconomics2020
International Valuation Protocol for the EQ-5D-Y-3L.
Article in PharmacoEconomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Measurement Properties of the EQ-5D Instruments in Children and Adolescents: A Systematic Review.Applied health economics and health policy · 2025Pooled it
- How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review.PharmacoEconomics · 2025Pooled it
- A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets.PharmacoEconomics · 2022Pooled it
- Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures.PharmacoEconomics · 2022Pooled it
- The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete Choice Experiment.PharmacoEconomics · 2026Trial
- The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.Lancet (London, England) · 2021Trial
- The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.Lancet (London, England) · 2021Trial
- Article
- Justifying and Classifying Adults' Roles in Child Health State Valuation: A Novel Taxonomy.PharmacoEconomics · 2026Review
- Economic Burden of Congenital Cytomegalovirus Disease on Families in the United States.Viruses · 2026Article
- Remote versus face-to-face delivery of the Group Triple P parenting programme: a feasibility non-randomised trial.Pilot and feasibility studies · 2026Article
- The Use of EQ-5D for Assessment of Health-Related Quality of Life and Its Determinants in Children with Complex Endocrine Conditions.Hormone research in paediatrics · 2026Article
- Child- versus adult-perspective composite time trade-off valuations for the EQ-5D-Y-3L: evidence from the Hungarian valuation study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- The Canadian Fontan Connection (CANFON): Protocol for a National Lifespan Cohort of People Living With a Fontan Circulation.CJC pediatric and congenital heart disease · 2026Article
- Valuation of the EQ-5D-Y-5L Using DCE Methods That Account for Nonlinear Time Preferences.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Value set of EQ-5D-Y-3L for Hong Kong.Health and quality of life outcomes · 2026Article
- Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Valuing health states for infants and toddlers: challenges and methodological considerations in EQ-TIPS preference elicitation.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- EQ-5D(-Y) Valuation from Adult and Child Perspectives: Where Does the Empirical Evidence Leave Us and How Should We Proceed?PharmacoEconomics · 2026Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EQ-5D-Y-3L is a generic, health-related, quality-of-life instrument for use in younger populations. Some methodological studies have explored the valuation of children's EQ-5D-Y-3L health states. There are currently no published value sets available for the EQ-5D-Y-3L that are appropriate for use in a cost-utility analysis. The aim of this article was to describe the development of the valuation protocol for the EQ-5D-Y-3L instrument. There were several research questions that needed to be answered to develop a valuation protocol for EQ-5D-Y-3L health states. Most important of these were: (1) Do we need to obtain separate values for the EQ-5D-Y-3L, or can we use the ones from the EQ-5D-3L? (2) Whose values should we elicit: children or adults? (3) Which valuation methods should be used to obtain values for child's health states that are anchored in Full health = 1 and Dead = 0? The EuroQol Research Foundation has pursued a research programme to provide insight into these questions. In this article, we summarized the results of the research programme concluding with the description of the features of the EQ-5D-Y-3L valuation protocol. The tasks included in the protocol for valuing EQ-5D-Y-3L health states are discrete choice experiments for obtaining the relative importance of dimensions/levels and composite time-trade-off for anchoring the discrete choice experiment values on 1 = Full Health and 0 = Dead. This protocol is now available for use by research teams to generate EQ-5D-Y-3L value sets for their countries allowing the implementation of a cost-utility analysis for younger populations.
Indexed as
Identifiers
32297224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.